VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Other Events
ME Staff 8-k
VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Other EventsItem 8.01. Other Events
On September6, 2017, VIVUS,Inc. issued a press release titled “VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension.” A copy of the press release is attached hereto as Exhibit99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
ExhibitNo.
Description
99.1
Press Release issued by VIVUS,Inc. dated September6, 2017.
VIVUS INC ExhibitEX-99.1 2 a17-21404_1ex99d1.htm EX-99.1 Exhibit 99.1 VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension CAMPBELL,…To view the full exhibit click here About VIVUS,INC. (NASDAQ:VVUS) VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity. VIVUS,INC. (NASDAQ:VVUS) Recent Trading Information VIVUS,INC. (NASDAQ:VVUS) closed its last trading session down -0.009 at 0.871 with 1,452,331 shares trading hands.